Takeda hands TiGenix a rare, $434M marketing deal for PhIII stem cell therapy
Belgian biotech TiGenix triggered a rare round of enthusiasm for stem cell research a couple of years back with news its lead off-the-shelf therapy hit the primary endpoint in a Phase III study treating fistulas in Crohn’s disease patients. They backed it up a year later with even more positive data. And now, a few months after it was filed for approval, Takeda is buying its way in with a small deal to acquire the European rights to Cx601.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
